Cybrexa Therapeutics Secures $13.4M Series B Funding to Advance Alphalex Drug Delivery Platform Targeting Cancer Drug Resistance

VCBeat (WeChat ID: vcbeat) learned from foreign media that on June 20, U.S. local time, medical technology company Cybrexa Therapeutics completed a $13.4 million Series B financing round. The funds from this round will be used to support the company in advancing its clinical program research, helping cancer patients address drug resistance issues.

Cybrexa Therapeutics, founded in 2017 and headquartered in Connecticut, USA, is a medical technology company focused on innovative cancer therapies.

Cancer, also known as malignant tumor, is contrasted with benign tumor. Cancer is a disease caused by the loss of normal regulatory control in body cells, leading to excessive cell proliferation. The excessively proliferating cells in the human body are called cancer cells, which can invade surrounding tissues and even metastasize to other parts of the body through the circulatory or lymphatic systems; this process is referred to as cancer spread. There are many types of cancer, and the severity of the condition depends on the location of the cancer cells, their degree of malignancy, and whether metastasis has occurred. Once diagnosed, patients need to receive treatment options such as surgery, chemotherapy, and radiation therapy.

Cancer patients need to combine anticancer drugs with the aforementioned treatments to control their condition. Currently, approximately 130–150 anticancer drugs have been approved for marketing worldwide. Although there is a wide variety of these drugs, their therapeutic mechanisms are fundamentally similar: after entering the human body, they target cancerous cells and bind to cell surface antigens, thereby entering the cells and activating intracellular self-degradation genes to reduce the number of cancer cells. However, as the duration of drug administration increases, cancer cells develop resistance to the same drug. Consequently, when the drug reaches the extracellular space, it can no longer bind to the cell surface antigens, failing to induce the degradation of a large number of cancer cells.

Cybrexa Therapeutics’ flagship product, Alphalex, is a drug delivery platform that addresses issues such as cellular drug resistance. When anticancer drugs are administered via the Alphalex platform, they can directly enter cancerous cells without needing to bind to cell-surface antigens. The therapeutic process of this platform involves the following steps: systemic administration of the drug, modulation of the body’s pH environment, loosening of cellular structures under low-pH conditions, and subsequent intracellular drug delivery.

The treatment regimen on the Alphalex platform addresses the challenges faced by patients requiring periodic medication. Utilizing this platform for disease management not only mitigates issues such as cellular drug resistance but also helps reduce partial treatment costs for cancer patients.

Cybrexa Therapeutics, Inc. plans to continue advancing clinical studies of its alphalex platform to enhance the precision of drug and cell delivery, while expanding the range of treatable diseases to serve more cancer patients.

Per Hellsund, President and Chief Executive Officer of Cybrexa Therapeutics, stated: “Cancer has always been a key focus for the industry. We aim to develop novel therapies to help cancer patients alleviate suffering and recover their health sooner. We will leverage the funds from this investment to advance the next phase of clinical studies for our novel therapies, with the goal of bringing these new cancer treatments to market as early as possible.”

(Compiled by Liu Yujing)